JP2010526541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526541A5 JP2010526541A5 JP2010507728A JP2010507728A JP2010526541A5 JP 2010526541 A5 JP2010526541 A5 JP 2010526541A5 JP 2010507728 A JP2010507728 A JP 2010507728A JP 2010507728 A JP2010507728 A JP 2010507728A JP 2010526541 A5 JP2010526541 A5 JP 2010526541A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide decoy
- transcription factor
- sequence
- composition
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- 102000040945 Transcription factor Human genes 0.000 claims description 40
- 108091023040 Transcription factor Proteins 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 12
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 10
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 8
- 102100027313 Calsenilin Human genes 0.000 claims description 8
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 8
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 8
- 102100032057 ETS domain-containing protein Elk-1 Human genes 0.000 claims description 8
- 102100035075 ETS-related transcription factor Elf-1 Human genes 0.000 claims description 8
- 101000914063 Eucalyptus globulus Leafy/floricaula homolog FL1 Proteins 0.000 claims description 8
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 8
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 8
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 8
- 101000726098 Homo sapiens Calsenilin Proteins 0.000 claims description 8
- 101000877395 Homo sapiens ETS-related transcription factor Elf-1 Proteins 0.000 claims description 8
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 claims description 8
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims description 8
- 101001139117 Homo sapiens Krueppel-like factor 7 Proteins 0.000 claims description 8
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 claims description 8
- 101001094741 Homo sapiens POU domain, class 4, transcription factor 1 Proteins 0.000 claims description 8
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 8
- 101001096159 Homo sapiens Pituitary-specific positive transcription factor 1 Proteins 0.000 claims description 8
- 101000881764 Homo sapiens Transcription elongation factor 1 homolog Proteins 0.000 claims description 8
- 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 claims description 8
- 101000744900 Homo sapiens Zinc finger homeobox protein 3 Proteins 0.000 claims description 8
- 102000043138 IRF family Human genes 0.000 claims description 8
- 108091054729 IRF family Proteins 0.000 claims description 8
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims description 8
- 102100020692 Krueppel-like factor 7 Human genes 0.000 claims description 8
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 claims description 8
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 claims description 8
- 102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 claims description 8
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 8
- 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 claims description 8
- 101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 claims description 8
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 claims description 8
- 108010042291 Serum Response Factor Proteins 0.000 claims description 8
- 102100022056 Serum response factor Human genes 0.000 claims description 8
- 101000805921 Strongylocentrotus purpuratus Upstream stimulatory factor Proteins 0.000 claims description 8
- 102100040296 TATA-box-binding protein Human genes 0.000 claims description 8
- 101710145783 TATA-box-binding protein Proteins 0.000 claims description 8
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 claims description 8
- 102100040105 Upstream stimulatory factor 1 Human genes 0.000 claims description 8
- 101000671634 Xenopus borealis Upstream stimulatory factor 1 Proteins 0.000 claims description 8
- 102100039966 Zinc finger homeobox protein 3 Human genes 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 101150014102 mef-2 gene Proteins 0.000 claims description 8
- 102100031690 Erythroid transcription factor Human genes 0.000 claims description 6
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 claims description 6
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims description 6
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 6
- 102100035251 Protein C-ets-1 Human genes 0.000 claims description 6
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 6
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 6
- 230000008055 nociceptive signaling Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- -1 IKZF Proteins 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 102000005869 Activating Transcription Factors Human genes 0.000 claims description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 claims description 2
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 claims description 2
- 102000017679 HTR3A Human genes 0.000 claims description 2
- 101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 claims description 2
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 claims description 2
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 claims description 2
- 101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 claims description 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims description 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims description 2
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 claims description 2
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 claims description 2
- 102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 238000000034 method Methods 0.000 description 16
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758307P | 2007-05-11 | 2007-05-11 | |
| US60/917,583 | 2007-05-11 | ||
| PCT/US2008/063471 WO2008141308A2 (en) | 2007-05-11 | 2008-05-12 | Gene expression and pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149516A Division JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526541A JP2010526541A (ja) | 2010-08-05 |
| JP2010526541A5 true JP2010526541A5 (cg-RX-API-DMAC7.html) | 2012-04-05 |
| JP5646320B2 JP5646320B2 (ja) | 2014-12-24 |
Family
ID=40002879
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507728A Expired - Fee Related JP5646320B2 (ja) | 2007-05-11 | 2008-05-12 | 遺伝子発現と疼痛 |
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
| JP2015207655A Expired - Fee Related JP6082796B2 (ja) | 2007-05-11 | 2015-10-22 | 遺伝子発現と疼痛 |
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
| JP2015207655A Expired - Fee Related JP6082796B2 (ja) | 2007-05-11 | 2015-10-22 | 遺伝子発現と疼痛 |
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US7943591B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2158316B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP5646320B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008251320B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2723672C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2158316T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2619314T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20150759T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE025701T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2158316T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2158316E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2158316T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008141308A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150759T1 (hr) * | 2007-05-11 | 2015-08-14 | Adynxx, Inc. | Ekspresija gena i bolovi |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
| WO2011029092A1 (en) | 2009-09-04 | 2011-03-10 | University Of Miami | Klf family members regulate intrinsic axon regeneration ability |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| ES2626488T3 (es) | 2011-07-19 | 2017-07-25 | Wave Life Sciences Pte. Ltd. | Procedimientos para la síntesis de ácidos nucleicos funcionalizados |
| EP2755636A1 (en) | 2011-09-16 | 2014-07-23 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Amphiphilic cationic polymers for the delivery of therapeutic agents |
| US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
| PT2846839T (pt) | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
| ES2940887T3 (es) | 2012-07-13 | 2023-05-12 | Wave Life Sciences Ltd | Método de preparación de oligonucleótidos quirales |
| BR112015000723A2 (pt) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
| GB201310853D0 (en) * | 2013-06-18 | 2013-07-31 | Ucb Pharma Sa | Method |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| BR112017002629A2 (pt) | 2014-08-15 | 2018-02-20 | Adynxx, Inc. | decoys de oligonucleotídeo para o tratamento de dor |
| JP6993230B2 (ja) * | 2015-09-09 | 2022-01-13 | アンジェス株式会社 | キメラデコイ |
| WO2017151644A1 (en) * | 2016-02-29 | 2017-09-08 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
| WO2024044770A1 (en) * | 2022-08-26 | 2024-02-29 | Core Biotherapeutics, Inc. | Oligonucleotides for the treatment of breast cancer |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5272056A (en) | 1991-01-03 | 1993-12-21 | The Research Foundation Of State University Of New York | Modification of DNA and oligonucleotides using metal complexes of polyaza ligands |
| WO1992018522A1 (en) | 1991-04-18 | 1992-10-29 | The Salk Institute For Biological Studies | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| EP0771320A4 (en) | 1993-07-29 | 1998-11-25 | Univ California | POLYNUCLEOTIDE LURES INHIBITING THE EXPRESSION OF MAJOR II HISTOCOMPATIBILITY COMPLEX, AND APPLICATIONS |
| PT732929E (pt) | 1993-10-29 | 2008-08-26 | Brigham & Womens Hospital | Utilização terapêutica de ''engodos'' de elementos cis in vivo |
| JP3392143B2 (ja) | 1994-11-17 | 2003-03-31 | 大鵬薬品工業株式会社 | 二本鎖オリゴヌクレオチド及びこれを有効成分とする制癌剤 |
| AU5369396A (en) | 1995-03-23 | 1996-10-08 | Research Foundation Of The State University Of New York, The | Rest protein and dna |
| ES2220929T3 (es) | 1995-05-11 | 2004-12-16 | Applied Research Systems Ars Holding N.V. | Inhibidor de la actividad il-6. |
| ES2285712T3 (es) | 1995-05-12 | 2007-11-16 | Anges Mg, Inc. | Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b. |
| GB9515356D0 (en) | 1995-07-26 | 1995-09-20 | Medical Res Council | Improvements in or relating to delivery of nucleic acid |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| AU737926B2 (en) | 1996-05-20 | 2001-09-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligonucleotides which specifically bind retroviral nucleocapsid proteins |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| JP4215219B2 (ja) | 1997-07-04 | 2009-01-28 | アンジェスＭｇ株式会社 | 脳保護剤 |
| JP3667047B2 (ja) | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| AU9692198A (en) | 1997-10-10 | 1999-05-03 | Kevin J. Donahue | Gene delivery compositions and methods |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| JP2002508386A (ja) | 1997-12-16 | 2002-03-19 | ザ・ユニバーシティー・オブ・サスカチワン・テクノロジーズ・インコーポレーテッド | 導電性金属含有核酸 |
| EA200001124A1 (ru) | 1998-06-02 | 2001-08-27 | Глаксо Груп Лимитед | Способ генной терапии |
| US6818626B1 (en) | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
| US6423493B1 (en) | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
| US6008048A (en) | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
| US7160869B2 (en) | 1998-12-16 | 2007-01-09 | University Of Saskatchewan | Biologically active metal-containing nucleic acids |
| AU761136B2 (en) | 1998-12-23 | 2003-05-29 | Genentech Inc. | Transfectacons comprising calcium phosphate and a nucleic acid |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6333408B1 (en) | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| CA2300328A1 (en) | 1999-09-14 | 2001-03-14 | Cardiogene Gentherap. Systeme Ag | Modulating transcription of genes in vascular cells |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
| DE10049549A1 (de) | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| WO2002030355A2 (en) | 2000-10-11 | 2002-04-18 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| US20040077573A1 (en) | 2000-11-24 | 2004-04-22 | Hiroki Maruyama | Method for regulating the activity of an expression product of a gene transferred into living body |
| US20020137715A1 (en) | 2001-01-03 | 2002-09-26 | Alain Mauviel | Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis |
| US7060690B2 (en) | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
| TWI308492B (cg-RX-API-DMAC7.html) | 2001-02-20 | 2009-04-11 | Anges Mg Inc | |
| US20070122401A1 (en) | 2001-03-06 | 2007-05-31 | Andrews William H | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| US20030166555A1 (en) | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
| EP1298141A1 (en) | 2001-09-27 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2 |
| DE10148828B4 (de) | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation der Expression STAT-1-abhängiger Gene |
| US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| MXPA04007124A (es) | 2002-02-01 | 2004-10-29 | Omeros Corp | Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago. |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| KR100874798B1 (ko) | 2002-04-26 | 2008-12-19 | 이인규 | 전사시 ｄｎａ 결합부위를 포함하는 원형의 아령형 디코이올리고뉴클레오티드 |
| DE10242319A1 (de) | 2002-09-12 | 2004-03-25 | Avontec Gmbh | Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens |
| DE10257421A1 (de) | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
| KR20120068035A (ko) | 2002-12-09 | 2012-06-26 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| EP1644532A4 (en) | 2003-06-30 | 2007-11-28 | Massachusetts Inst Technology | EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA |
| US20080233644A1 (en) * | 2003-09-12 | 2008-09-25 | Helen Fillmore | Chimeric Transcription Factor Decoy Oligonucleotides |
| JP2005336081A (ja) | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤 |
| US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| WO2006012625A2 (en) | 2004-07-22 | 2006-02-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Stat3 decoy oligonucleotides and uses therefor |
| WO2006034433A2 (en) | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| KR101357016B1 (ko) | 2004-09-28 | 2014-02-03 | 쿠아크 파마수티칼스 인코퍼레이티드 | 탈모증, 급성신부전증 및 다른 질환의 치료를 위한올리고리보뉴클레오티드 및 그것의 사용방법 |
| US8067384B2 (en) * | 2004-10-22 | 2011-11-29 | Anges Mg, Inc. | Chimera (double) decoy |
| US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| WO2006096498A2 (en) * | 2005-03-04 | 2006-09-14 | Dana-Farber Cancer Institute, Inc. | Regulation of runx1 for treatment of pain |
| US7680060B2 (en) * | 2005-03-08 | 2010-03-16 | Cisco Technology, Inc. | Transferring state information in a network |
| WO2006104913A2 (en) | 2005-03-25 | 2006-10-05 | Medtronic, Inc. | USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN |
| JP2010505556A (ja) | 2006-10-09 | 2010-02-25 | ニューロフルーディクス， インコーポレイテッド | 脳脊髄液精製システム |
| EP2146691A2 (en) | 2007-04-17 | 2010-01-27 | Baxter International Inc. | Nucleic acid microparticles for pulmonary delivery |
| HRP20150759T1 (hr) | 2007-05-11 | 2015-08-14 | Adynxx, Inc. | Ekspresija gena i bolovi |
| PH12013500192B1 (en) | 2010-08-20 | 2018-11-23 | Replicor Inc | Oligonucleotide chelate complexes |
| US20140275211A1 (en) | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| AU2012283915B2 (en) | 2011-07-20 | 2016-11-24 | Hospira, Inc. | Methods of treating pain |
| PT2846839T (pt) | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
| TWI635864B (zh) | 2012-05-18 | 2018-09-21 | 雷普利可公司 | 寡核苷酸螯合複合物－多肽組合物及方法 |
| BR112017002629A2 (pt) | 2014-08-15 | 2018-02-20 | Adynxx, Inc. | decoys de oligonucleotídeo para o tratamento de dor |
| WO2017151644A1 (en) | 2016-02-29 | 2017-09-08 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
-
2008
- 2008-05-12 HR HRP20150759TT patent/HRP20150759T1/hr unknown
- 2008-05-12 ES ES14179247.3T patent/ES2619314T3/es active Active
- 2008-05-12 SI SI200831461T patent/SI2158316T1/sl unknown
- 2008-05-12 EP EP08755344.2A patent/EP2158316B1/en not_active Not-in-force
- 2008-05-12 DK DK08755344.2T patent/DK2158316T3/en active
- 2008-05-12 PT PT87553442T patent/PT2158316E/pt unknown
- 2008-05-12 ES ES08755344.2T patent/ES2542511T3/es active Active
- 2008-05-12 PL PL08755344T patent/PL2158316T3/pl unknown
- 2008-05-12 CA CA2723672A patent/CA2723672C/en active Active
- 2008-05-12 WO PCT/US2008/063471 patent/WO2008141308A2/en not_active Ceased
- 2008-05-12 US US12/119,435 patent/US7943591B2/en not_active Expired - Fee Related
- 2008-05-12 EP EP16199871.1A patent/EP3199635B1/en not_active Not-in-force
- 2008-05-12 HU HUE08755344A patent/HUE025701T2/en unknown
- 2008-05-12 AU AU2008251320A patent/AU2008251320B2/en not_active Ceased
- 2008-05-12 JP JP2010507728A patent/JP5646320B2/ja not_active Expired - Fee Related
- 2008-05-12 EP EP14179247.3A patent/EP2818550B1/en not_active Not-in-force
-
2011
- 2011-03-15 US US13/048,793 patent/US8093225B2/en not_active Expired - Fee Related
- 2011-12-09 US US13/316,321 patent/US8741864B2/en active Active - Reinstated
-
2014
- 2014-04-22 US US14/258,927 patent/US9290762B2/en not_active Expired - Fee Related
- 2014-07-23 JP JP2014149516A patent/JP5890869B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-22 JP JP2015207655A patent/JP6082796B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,791 patent/US10041069B2/en active Active
- 2016-03-28 JP JP2016064037A patent/JP6306075B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-30 JP JP2017106521A patent/JP2017148074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526541A5 (cg-RX-API-DMAC7.html) | ||
| CA2723672C (en) | Gene expression and pain | |
| JP2013510561A5 (cg-RX-API-DMAC7.html) | ||
| JP2016014070A5 (cg-RX-API-DMAC7.html) | ||
| Shern et al. | Pediatric rhabdomyosarcoma | |
| JP2018534950A5 (cg-RX-API-DMAC7.html) | ||
| Deb et al. | Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer | |
| JP2004537260A5 (cg-RX-API-DMAC7.html) | ||
| JP2015534817A5 (cg-RX-API-DMAC7.html) | ||
| Pumbwe et al. | BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2015504650A5 (cg-RX-API-DMAC7.html) | ||
| JP2016502858A5 (cg-RX-API-DMAC7.html) | ||
| JP2012505657A5 (cg-RX-API-DMAC7.html) | ||
| Le Grice | Targeting the HIV RNA genome: high-hanging fruit only needs a longer ladder | |
| JP2006518372A5 (cg-RX-API-DMAC7.html) | ||
| WO2007146511A3 (en) | Compounds and methods for modulating gene expression | |
| JP2008513513A5 (cg-RX-API-DMAC7.html) | ||
| JP2014504857A5 (cg-RX-API-DMAC7.html) | ||
| JP2010515707A5 (cg-RX-API-DMAC7.html) | ||
| Harvey et al. | Repetitive sequence variations in the promoter region of the adhesin-encoding gene sabA of Helicobacter pylori affect transcription | |
| CN107805643B (zh) | 靶向抑制沙门氏菌耐药外排泵基因acrA的siRNA-DNA纳米系统及其制备方法 | |
| JP2013537404A5 (cg-RX-API-DMAC7.html) | ||
| CN104487096B (zh) | 用于活性成分递送的配制物 | |
| AU2019414608A1 (en) | Oligomeric nucleic acid molecule and application thereof |